← Leaderboards
Gilbert C. White
University Of North Carolina Chapel Hill
$11,716,605
Attributed
$11,716,605
Total exposure
17
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.7M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$17,674,543 · 18
By mechanism
P01$8,069,871 · 5
C06$2,932,669 · 1
M01$2,914,493 · 7
T32$1,646,433 · 1
R01$1,506,077 · 2
U01$600,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Darrel W Stafford$14,989,135
- Timothy Charles Nichols$20,287,823
- Gerardo Heiss$39,428,129
- Winston C Patterson$23,185,986
- Frank C Church$1,886,174
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationHemophilia AsBlood Disorder ChemotherapyCoagulation Factor ViiiRecombinant ProteinsClinical Trial Phase IIntegrinsTransfusionMedicineHemostasisResearch TrainingProtein Structure FunctionHepatitis CRibavirinBlood Coagulation DisordersCombination ChemotherapyMaleLiver Disorder ChemotherapyPharmacokineticsInterferon AlphaProtein Binding
Grant awards (62)
Research Training In Transfusion Medicine$146,178
T32 · FY2019 · HL · contact PI
Research Training In Transfusion Medicine$266,484
T32 · FY2018 · HL · contact PI
Research Training In Transfusion Medicine$281,422
T32 · FY2017 · HL · contact PI
Research Training In Transfusion Medicine$2,560
T32 · FY2017 · HL · contact PI
Research Training In Transfusion Medicine$272,622
T32 · FY2016 · HL · contact PI
Research Training In Transfusion Medicine$257,571
T32 · FY2015 · HL · contact PI
Research Training In Transfusion Medicine$140,770
T32 · FY2012 · HL · contact PI
Research Training In Transfusion Medicine$106,855
T32 · FY2011 · HL · contact PI
Initiative in Stem Cell Biology$2,932,669
C06 · FY2010 · RR · contact PI
Role of Carboxyterminal Hypervariable Region in Rap1b Function$593,203
R01 · FY2010 · HL · contact PI
Research Training In Transfusion Medicine$171,971
T32 · FY2010 · HL · contact PI
Blood Dyscrasias and Transfusion Medicine$5,000
R13 · FY2010 · HL · contact PI
Role of Carboxyterminal Hypervariable Region in Rap1b Function$580,127
R01 · FY2009 · HL · contact PI
THE ROLE OF RAP1 IN INTEGRIN ACTIVATION AND PLATELET SIGNALING$376,868
P01 · FY2007 · HL · contact PI
THE ROLE OF RAP1 IN INTEGRIN ACTIVATION AND PLATELET SIGNALING$358,264
P01 · FY2006 · HL · contact PI
ADMINISTRATIVE CORE$94,713
P01 · FY2006 · HL · contact PI
Role of Rap1b in Integrin Activation and Platelet Signaling$358,405
P01 · FY2005 · HL
EXTENSION STUDY TO CHARACTERIZE BDDRFVIII MANUFACTURED BY REFACTO AF$2,199
M01 · FY2005 · RR
Role of Rap1b in Integrin Activation and Platelet Signaling$350,085
P01 · FY2004 · HL
Core A-- Adminsitrative Core$93,129
P01 · FY2004 · HL
Structure and Function of Vascular Integrins$1,851,988
P01 · FY2003 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2003 · HL
STRUCTURE/FUNCTION OF VASCULAR INTEGRINS$1,403,872
P01 · FY2002 · HL
Transfusion Medicine/Hemostasis Clinical Research Netwo*$300,000
U01 · FY2002 · HL
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$190,747
M01 · FY2002 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$190,747
M01 · FY2002 · RR
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$190,747
M01 · FY2002 · RR
STRUCTURE AND FUNCTION OF THE BETA CYTOPLASMIC DOMAINS$110,268
P01 · FY2002 · HL
STRUCTURE/FUNCTION OF VASCULAR INTEGRINS$1,368,314
P01 · FY2001 · HL
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$294,555
M01 · FY2001 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$294,555
M01 · FY2001 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$294,555
M01 · FY2001 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$190,747
M01 · FY2001 · RR
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$190,747
M01 · FY2001 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$190,747
M01 · FY2001 · RR
STRUCTURE AND FUNCTION OF THE BETA CYTOPLASMIC DOMAINS$110,268
P01 · FY2001 · HL
STRUCTURE/FUNCTION OF VASCULAR INTEGRINS$1,333,764
P01 · FY2000 · HL
PLATELET SPECIFIC KNOCKOUT OF SIGNALING PROTEINS$332,747
R01 · FY2000 · HL
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$294,555
M01 · FY2000 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$294,555
M01 · FY2000 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$294,555
M01 · FY2000 · RR
STRUCTURE AND FUNCTION OF THE BETA CYTOPLASMIC DOMAINS$259,933
P01 · FY2000 · HL
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$241
M01 · FY2000 · RR
ANTIHEMOPHILIC FACTOR (AF RAHF) IN PREV TREATED SEVERE HEMOPHILIA A$241
M01 · FY2000 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$0
M01 · FY2000 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$0
M01 · FY2000 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$0
M01 · FY2000 · RR
ANTIRETRIVIRAL THERAPY &INDINAVIR SULFATE IN HIV-1 HEMOPHILIA$0
M01 · FY2000 · RR
ANTIRETRIVIRAL THERAPY &INDINAVIR SULFATE IN HIV-1 HEMOPHILIA$0
M01 · FY2000 · RR
ANTIRETRIVIRAL THERAPY &INDINAVIR SULFATE IN HIV-1 HEMOPHILIA$0
M01 · FY2000 · RR
ANTIRETRIVIRAL THERAPY &INDINAVIR SULFATE IN HIV-1 HEMOPHILIA$0
M01 · FY2000 · RR
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$0
M01 · FY2000 · RR
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$0
M01 · FY2000 · RR
RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A$0
M01 · FY2000 · RR
PREDICTORS OF INHIBITORS IN HEMOPHILIA A$0
M01 · FY2000 · RR
PREDICTORS OF INHIBITORS IN HEMOPHILIA A$0
M01 · FY2000 · RR
PREDICTORS OF INHIBITORS IN HEMOPHILIA A$0
M01 · FY2000 · RR
FACTOR VIII VECTOR FOR TREATMENT OF SEVERE HEMOPHILIA A$0
M01 · FY2000 · RR
FACTOR VIII VECTOR FOR TREATMENT OF SEVERE HEMOPHILIA A$0
M01 · FY2000 · RR
FACTOR VIII VECTOR FOR TREATMENT OF SEVERE HEMOPHILIA A$0
M01 · FY2000 · RR
FACTOR VIII VECTOR FOR TREATMENT OF SEVERE HEMOPHILIA A$0
M01 · FY2000 · RR
R97 022: INTRON A + RIBAVIRIN FOR HEPATITIS C &INHERITED COAGULATION DISEASE$0
M01 · FY2000 · RR